Association of XPD and XRCC1 Genetic Polymorphisms with Hepatocellular Carcinoma Risk

Guo, Lianyi; Jin, Xu-Peng; Niu, Wei; Li, Xiaofei; Liu, Baohai; Wang, Yulin

doi:10.7314/apjcp.2012.13.9.4423

Cited by 28 publications

(26 citation statements)

References 21 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, molecular epidemiological studies have investigated the effect of these two polymorphisms on the risk of HCC (9)(10)(11)(12)(13)(14)(15)(16)(17)(18); however, the results obtained in these studies have been inconsistent, particularly in an Asian population. In addition, the majority of studies have solely examined the effect of XPD polymorphisms, while only a few studies have explored the interaction of XPD with HBV and other environmental factors.…”

Section: Introductionmentioning

confidence: 94%

“…A total of 11 studies (9-18; Yu, unpublished data) were ultimately included in this meta-analysis based on the search strategy and inclusion criteria. Four of the 11 studies examined both the XPD Lys Gln polymorphism (9-18; Yu, unpublished data) and four studies (1,753 HCC cases and 1,914 controls) for the XPD Asp 312 Asn polymorphism (11,13,15,17) were retrieved in the final meta-analysis. The characteristics of the included studies are listed in Tables I and II Gene-HBV interaction.…”

mentioning

confidence: 99%

See 1 more Smart Citation

XPD Lys751Gln and Asp312Asn polymorphisms and hepatocellular carcinoma susceptibility: A meta-analysis of 11 case-control studies in an Asian population

Yang

Wei

Zhang

et al. 2015

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. This meta-analysis was performed to evaluate the association between xeroderma pigmentosum complementary group D (XPD) Lys Gln polymorphism could be a potential biomarker of HCC susceptibility and that the XPD Lys 751 Gln and Asp 312 Asn polymorphisms could be risk factors for HCC susceptibility in an Asian population; however, further large-scale and well-designed studies are required to reach a more precise and comprehensive conclusion.

show abstract

Section: Introductionmentioning

confidence: 94%

mentioning

confidence: 99%

XPD Lys751Gln and Asp312Asn polymorphisms and hepatocellular carcinoma susceptibility: A meta-analysis of 11 case-control studies in an Asian population

Yang

Wei

Zhang

et al. 2015

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

“…Among these, five papers (Zhang et al, 2010;Liu et al, 2011;Xie et al, 2012;Li et al, 2013;Zeng et al, 2013) which were meta-analysis papers, four studies which were conducted (Yu et al, 2003;Han et al, 2004;Long , 2004;Han et al, 2012) on the same population, four (Long et al, 2008;Ding et al, 2012;Jung et al, 2012) papers not providing adequate data for calculation of OR and 95% CI, and four Su et al, 2008;Guo et al, 2012;Bose et al, 2013) studies not in accordance with HWE were excluded. A flow diagram summarizing the process of study selection was illustrated in Figure 1.…”

Section: Characteristics Of Studiesmentioning

confidence: 99%

The XRCC1 Arg399Gln Genetic Polymorphism Contributes to Hepatocellular Carcinoma Susceptibility: An Updated Meta-analysis

Pan¹,

Zhao²,

Chen³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

The potential correlation of X-ray repair cross-complementing group 1 (XRCC1) Arg399Gln polymorphism with hepatocellular carcinoma (HCC) susceptibility is ambiguous. Taking account of inconsistent results of previous meta-analyses and new emerging literatures, we conducted a meta-analysis covering 15 case-control datasets to evaluate the relationship. Relevant studies from Medline, Embase and CNKI were retrieved. A fixedeffect model or a random-effect model, depending on between-study heterogeneity, were applied to estimate the association between XRCC1 polymorphism Arg399Gln and HCC risk with the results presented as odds ratios (ORs) and 95% confidence intervals (95% CIs). In accordance with Hardy-Weinberg equilibrium, 15 studies with data for 6,556 individuals were enrolled in this systematic review.

show abstract

“…On the whole, three newly updated meta-analyses revealed that there were no evidence supporting that XPD Lys751Gln polymorphism contributed to prostate cancer (Ma et al, 2013) , colorectal cancer (Zhang et al, 2011) , or gastric cancer (Yin et al, 2013). On the contrary, other large sample meta-analyses proposed a greater risk in hepatocellular carcinoma (Guo et al, 2012), breast cancer (Yan et al, 2014), lung cancer , glioma (Chen et al, 2012), and acute myeloid leukemia (AML) (Liu et al, 2014). For XPD Asp312Asn polymorphism, three meta-analyses proposed a greater risk in prostate cancer (Ma et al, 2013), gastric cancer (Yin et al, 2013), and esophageal cancer (Duan et al, 2012).…”

Section: Discussionmentioning

confidence: 99%

XPD Lys751Gln and Asp312Asn Polymorphisms and Susceptibility to Skin Cancer: A Meta-Analysis of 17 Case-control Studies

Zhu¹,

Bao²,

Lin³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Numerous studies have explored the influence of XPD Lys751Gln and/or Asp312Asn polymorphisms on skin cancer susceptibility. However, the results remain inconclusive. To derive a more precise estimation, we conducted a comprehensive search to identify all available published studies and performed a meta-analysis. Materials and Methods: Electronic literature searches of the PubMed, CBM and CNKI databases were performed up to March 2014. Odds ratios (ORs) with 95% confidence intervals (CIs) were applied to assess the strength of associations. Results: Seventeen case-control studies were included with a total sample size of 6, 113 cases and 11, 074 controls for the XPD Lys751Gln polymorphism, and 10 studies (3, 840cases and 7, 637 controls) for the XPD Asp312Asn polymorphism were pooled for analysis. Overall, no significant associations were found between the XPD Lys751Gln polymorphism and skin cancer risk in any genetic model. On stratified analysis by tumor type, XPD Lys751Gln polymorphism was not associated with increased risk of non-melanoma skin cancer, but was significantly related with increased risk of cutaneous melanoma (Gln/Gln vs Lys/Lys: OR=1.15, 95%CI=1.02-1.29, p=0.023; dominant model: OR=1.09, 95%CI=1.01-1.18, p=0.036). For the XPD Asp312Asn polymorphism, no significant association with skin cancer risk was observed in overall or subgroup analyses. Conclusions: The present meta-analysis suggests that the XPD Lys751Gln polymorphism may contribute to the risk of cutaneous melanoma from currently available evidence. Further investigations are needed to obtain more insight into possible roles of these two polymorphisms in skin carcinogenesis.

show abstract

Association of XPD and XRCC1 Genetic Polymorphisms with Hepatocellular Carcinoma Risk

Cited by 28 publications

References 21 publications

XPD Lys751Gln and Asp312Asn polymorphisms and hepatocellular carcinoma susceptibility: A meta-analysis of 11 case-control studies in an Asian population

XPD Lys751Gln and Asp312Asn polymorphisms and hepatocellular carcinoma susceptibility: A meta-analysis of 11 case-control studies in an Asian population

The XRCC1 Arg399Gln Genetic Polymorphism Contributes to Hepatocellular Carcinoma Susceptibility: An Updated Meta-analysis

XPD Lys751Gln and Asp312Asn Polymorphisms and Susceptibility to Skin Cancer: A Meta-Analysis of 17 Case-control Studies

Contact Info

Product

Resources

About